<DOC>
	<DOCNO>NCT02231658</DOCNO>
	<brief_summary>The present study compare lixisenatide liraglutide population subject T2DM optimally control OADs / insulin , target population medication .</brief_summary>
	<brief_title>Effects Victoza® ( Liraglutide ) Versus Lyxumia® ( Lixisenatide ) Gastroesophageal Reflux , Gastric Emptying Gastric Acid Secretion</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial . Male female age 1865 year ( inclusive ) T2DM diagnosis Contraindications ( include know suspected hypersensitivity ) GLP1 mimetics Use GLP1 mimetics DPPIV inhibitor Clinically relevant dysglycaemia indicate HbA1C ≥ 10 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>